Genomic Health Inc. (GHDX) suffered a third quarter loss of 2 cents per share, which was better than the Zacks Consensus Estimate of a loss of 9 cents. The company suffered a loss of 11 cents in the prior-year period.   Total revenues for the quarter came in at $39.5 million, compared with $28.1 million in the third quarter of 2008, up 40.6%. Product revenues from the Oncotype DX breast cancer test increased 39% to $38.9 million, compared with $28.1 million in the comparable quarter of 2008. Contract revenues accounted for the balance. In the third quarter, Genomic Health delivered in excess of 12,600 test results, compared with more than 10,220 test results in the comparable period of 2008, representing approximately a 23% year-over-year growth.   Research and development spend for the third quarter increased 31.9% to $9.1 million, compared to $6.9 million in the same period in ...

For Immediate Release

Chicago, IL – October 30, 2009 – Zacks Equity Research highlights CarMax (KMX) as the Bull of the Day and Genomic Health Inc. (GHDX) the Bear of the Day. In addition, Zacks Equity Research provides analysis on J.C. Penney (JCP), Macy’s (M) and Bank of America (BAC).

Full analysis of all these stocks is available at http://at.zacks.com/?id=2676

Here is a synopsis of all five stocks:

Bull of the Day:

CarMax (KMX) focuses on penetrating new markets through store openings. The company has kept its inventories closely aligned with sales trends, which has allowed it to optimize gross profit per unit besides offering great value to customers. These have helped the company to maintain a favorable position among its peer group.

CarMax has reported profit in the second quarter, reflecting a significant improvement from the Zacks Consensus Estimate. It

...

Here are the stocks added to the Zacks #5 Rank ("strong sell") List today:

Alon USA Energy Inc (ALJ) American Commercial Lines Inc (ACLI) American Vanguard Corp (AVD) Beacon Roofing Supply Inc (BECN) Capitol Federal Financial (CFFN) Canadian Imperial Bank of Commerce (CM) Cheniere Energy Inc (LNG) Chesapeake Utilities Corp (CPK) CRH Plc (CRH) CryptoLogic Ltd (CRYP) Delek US Holdings Inc (DK) First Financial Holdings Inc (FFCH) First Financial Service Corp (FFKY) Franklin Electric Co Inc (FELE) Gartner Inc (IT) General Cable Corp (BGC) ...

Here are the stocks added to the Zacks #5 Rank ("strong sell") List today:

American Commercial Lines Inc (ACLI) Arris Group Inc (ARRS) Associated Banc-Corp (ASBC) Astec Industries Inc (ASTE) Badger Meter Inc (BMI) Banner Corp (BANR) Beacon Roofing Supply Inc (BECN) Brunswick Corp (BC) C&D Technologies Inc (CHP) Capital Product Partners LP (CPLP) Capitol Federal Financial (CFFN) Ciber Inc (CBR) CIT Group Inc (CIT) Copano Energy LLC (CPNO) Crucell NV (CRXL) CryptoLogic Ltd (CRYP) Empresa Brasileira de Aeronautica SA (ERJ) ...

Recently, Genomic Health Inc. (GHDX) announced data which confirmed that manual micro dissection (dissection of tissue or cells under the microscope) of biopsy cavities is essential for the accurate assessment of recurrence risk in patients with early-stage breast cancer.  Genomic Health's Oncotype DX is the only commercially available breast cancer test that makes use of manual microdissection following review by a board certified surgical pathologist with expertise in breast cancer to predict a patient's benefit from chemotherapy and risk of disease recurrence.  The results from the study revealed that the inclusion of biopsy cavities in breast cancer specimens is associated with significant changes in the expression of individual genes. Consequently, it was found that biopsy cavities had high-risk Recurrence Scores.  Genomic also presented results which demonstrated ability of Oncotype DX breast cancer test to predict the likelihood of disease recurrence in Japanese women with estrogen ...

Here are the stocks added to the Zacks #5 Rank ("strong sell") List today:

Alexandria Real Estate Equities Inc (ARE) American Commercial Lines Inc (ACLI) Ameren Corp (AEE) Arris Group Inc (ARRS) Assisted Living Concepts Inc (ALC) Astec Industries Inc (ASTE) Blackrock Kelso Capital Corp (BKCC) CapLease Inc (LSE) Cascade Bancorp (CACB) Cheniere Energy Inc (LNG) Ciber Inc (CBR) Community Trust Bancorp Inc (CTBI) EnPro Industries Inc (NPO) Evergreen Solar Inc (ESLR) Fair Isaac Corp (FICO) First Industrial Realty Trust Inc (FR) ...

Yesterday, Genomic Health, Inc. (GHDX) announced that a number of leading U.S. surgeons ask for Genomic Health's Oncotype DX breast cancer assay at the time of surgery or biopsy, in an effort to provide patients with prompt, critical information about treatment options available at their maiden visit to an oncologist. Oncotype DX, the growth engine of the company, was launched in 2004. It is the first and only multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In late May 2009, Genomic Health announced that more than 100,000 test results have been delivered in over 40 countries worldwide since the commercial launch of Oncotype DX. The assay analyzes the activity of 21 genes within a breast cancer patient's tumor to calculate an individualized result (Recurrence Score). Upon ...